RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $235

Benzinga · 2d ago
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $234 to $235.